At aTENSION, we are redefining the future of hypertension care by setting new standards in precision diagnostics and personalized therapies. It is our mission to make advanced mass spectrometry diagnostics accessible to everyone.
We are offering solutions that enhance the well-being
and life quality of hypertensive patients while
supporting laboratories with precise and robust diagnostic solutions.
Find out more
our cutting-edge, reliable and easy-to-use testing platform. Valuable information about the underlying causes of uncontrolled high blood pressure can be obtained from just one blood sample. This serves as the basis for personalized treatment approaches – marking a breakthrough in hypertension diagnostics & patient care.
Get tested
Hypertension often goes undetected and secondary forms like primary aldosteronism frequently remain undiagnosed due to a low screening rate of only 1-2 %. Traditional ELISA-based diagnostic tests suffer from variability and drug interference, leaving clinicians to manage hypertension using a trial-and-error approach, often without identifying the underlying molecular causes. This leads to delayed blood pressure control, patient frustration, inappropriate medication, and an increased risk of cardiovascular complications.
At the forefront of precision medicine, our CE-IVD certified ALDO+ testing platform helps to identify the most common causes of uncontrolled hypertension, such as the detection of primary aldosteronism. By accurately analyzing key clinical hypertension parameters such as Angiotensin I, Angiotensin II and Aldosterone using mass spectrometry, it paves the way for a personalized and effective anti-hypertensive treatment and is set to establish itself as an essential screening tool for primary aldosteronism in routine diagnostics.
With our innovative Prep ‘n’ Ship™ approach we will make mass spectrometry-based diagnostics accessible to everyone. This approach allows clinicians and labs without mass spectrometry equipment to collect and prepare blood samples on-site and then ship them to specialized mass spectrometry labs for analyte quantification.. By bridging the gap between labs with and without mass spectrometers, this approach creates attractive opportunities for all laboratories and healthcare providers-enabling expanded diagnostic capabilities, optimized workflows, and increased access to cutting-edge hypertension screening.
Read more
The Prep ‘n’ Ship™ Model is designed to make our mass spectrometry-based ALDO+ testing platform accessible to all clinical labs, regardless of their mass spectrometry capabilities.
For labs with mass spectrometry capabilities, the Prep ‘n’ Ship™ model provides access to a large pool of prepared samples, maximizing the utilization of existing mass spectrometry infrastructure to generate additional revenue. These partner labs benefit from increased sample volume, optimized efficiency, and expanded collaboration with referring clinical labs. On the other hand, labs without mass spectrometry can now offer highly accurate diagnostic testing without investing in expensive mass spectrometry equipment generating additional income by collecting and preparing samples for partner labs. This model ultimately drives better patient outcomes, operational efficiency, and commercial advantages for all stakeholders in hypertension care.
Unlock new opportunities in precision diagnostics and become a reference lab in our ALDO+ network! Contact us today for more information
At its core, ALDO+ focuses on analyzing the Renin-Angiotensin-Aldosterone System (RAAS), a critical regulator of blood pressure and fluid balance in the body. A study published in Hypertension (Burrello et al., 2019) validates the ALDO+ diagnostic approach, formerly known as the RAAS Triple-A analysis, as an innovative tool for screening primary aldosteronism (PA), a common cause of secondary hypertension.
ALDO+ is transforming hypertension care with unparalleled benefits for clinicians, labs and patients, delivering high diagnostic value, operational simplicity, and cost efficiency.
Read more
For healthcare professionals, laboratories, and patients seeking in-depth insights, our Information Hub provides all essential resources in one place. Here, you can download key materials about our company, the clinical implications of ALDO+ testing, detailed guidance on result interpretation, and a directory of labs where the test is available. Whether you’re looking to integrate precision diagnostics into your practice, understand the benefits of mass spectrometry-based hypertension screening, or find a certified testing facility, you’ll find everything you need right here.
Press Release: aTENSION.life raises USD 3M in seed financing to bring precision diagnostics to 1.3 billion hypertensive patients
Download
Product Folder: Learn more about our first product - ALDO+PA - High Performance Screening for Primary Aldosteronism
Download
Doctor-Patient Guide: Detailed information on performing the test
Download
Test Assignment: Want to get tested? Please take this assignment with you to the lab/doctor!
Download
Hypertension Factsheet: Key facts about hypertension – causes, risks, and why early diagnosis matters.
Download
Company One-Pager: Concise overview of our mission and the potential of ALDO+ in hypertension diagnostics.
Download
Scientific Publication: Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism Burrello et al. (2019) demonstrate that AA2R is a reliable alternative to ARR for PA screening, even with ACE inhibitors.
Download
If you have any further questions or require additional information, feel free to contact us anytime.
We are committed to transform hypertension screening and profiling through innovative, precise and personalized diagnostic solutions. Backed by a global network of renowned hypertension experts, we leverage cutting-edge science to set new benchmarks in diagnostic excellence and patient care.
Short Bio
Short Bio
Short Bio
Short Bio
Whether you are a patient, doctor, lab, scientist, distributor or simply interested — we all have a connection to hypertension. Reach out to us today to learn more and work together on solutions!
Bernhard Klemen is co-founder and CEO of aTENSION.life. Via his family office he focuses as entrepreneurial investor on techbio/healthcare/diagnostics, deep-tech including fintech and emerging markets. He holds several board and advisory positions in his portfolio companies and in his focus sectors. Previously he acted among others as CFO and CBDO of Bit Bio Ltd. (synthetic biology), board member and co-founder of Clock Bio Ltd (rejuventation techbio), founding/general partner of Sarmayacar, a VC fund focused on Pakistan and CFO/co-founder in two SaaS companies.
Before his entrepreneurial career he spend about 10 years at UBS, Morgan Stanley and J.P.Morgan. He holds a PhD in economics and master-equivalents in law, business administration and economics.
Marko Poglitsch is Chief Scientific Officer at aTENSION.life, shaping the scientific vision and technological innovation in precision hypertension diagnostics. With a background in molecular biology and technical chemistry, he obtained his PhD in Immunology from the Medical University of Vienna. In 2012, he founded Attoquant Diagnostics, pioneering LC-MS/MS-based quantification of angiotensin peptides (RAS-Fingerprint™) for basic and clinical research worldwide. His decade of research and development at Attoquant led to key discoveries, including RAS equilibrium analysis and the AA2-Ratio, a novel biomarker for primary aldosteronism detection, culminating in the IVD-registration of the RAAS Triple-A™ kit. In 2024, Marko co-founded aTENSION.life, dedicated to transforming hypertension care by connecting laboratories, doctors, and patients through mass spectrometry-based RAAS diagnostics.
Katharina Wieser is Chief Business Officer at aTENSION.life, driving strategic growth and market positioning in precision hypertension diagnostics. With over 20 years of experience in strategic high-tech marketing, she has held leadership roles in biotech, life sciences, and diagnostics, including Division Marketing Officer at Romer Labs (DSM) and Head of Communications & Marketing of Themis Bioscience. Previously, she led corporate marketing and investor relations at Intercell (now Valneva), where she played a key role in the company’s IPO and subsequent SPO. Katharina has a track record in corporate strategy, brand building, product management, and investor relations. She also serves as a lecturer at IMC FH Krems. She holds a degree in International Business Administration from the University of Vienna and a specialization in Online Media Marketing.
Werner Lanthaler is the CEO of WLanholding GmbH and serves as Chairman at aTENSION.life. Werner has had a distinguished career in biotechnology, previously leading Evotec AG as CEO for nearly 15 years. Known for his forward-thinking approach, Werner was instrumental in transforming Evotec into a global leader in drug discovery and development, particularly in the realms of precision medicine and artificial intelligence. His vision helped streamline research collaborations and bring innovative therapies closer to market. Before joining Evotec, Werner held leadership positions across various industries, including serving as CFO of the biotech company Intercell AG, where he played a key role in taking the company public and successfully bringing vaccines to market. His commitment to transformation has been a consistent theme in his career, where he focused on integrating cutting-edge technologies to enhance the efficiency of drug development. Werner also serves on the Boards of FairJourney Biologics, HAL Allergy, Proxygen, AC Immune (NASDAQ) and Cerabyte GmbH and is an Advisory to several leading private equity firms (e.g. Hevolution, Forbion).
Our first product, the ALDO+PA Test, is a highly accurate blood test to diagnose primary aldosteronism, a common but underdiagnosed cause of treatment-resistant hypertension.
Cost: €183,20 (privately paid, potential reimbursement through your private insurance)
How it works:
Questions? Contact us at: aldotest@atension.life
